Current HIV/AIDS Reports

, 5:186

Adherence to biomedical HIV prevention methods: Considerations drawn from HIV treatment adherence research


DOI: 10.1007/s11904-008-0027-z

Cite this article as:
Stirratt, M.J. & Gordon, C.M. Curr HIV/AIDS Rep (2008) 5: 186. doi:10.1007/s11904-008-0027-z


Biomedical approaches to HIV prevention (eg, microbicides, antiretroviral preexposure prophylaxis) are undergoing clinical trials to test their efficacy. One key consideration emerging from completed trials is the critical role of adherence to the investigational product. Suboptimal product adherence may compromise clinical trial results and ultimately undermine the effectiveness of biomedical prevention methods in any future real-world use. Efforts to strengthen biomedical HIV prevention product adherence can benefit from existing research methodologies, findings, and interventions developed for adherence to HIV treatment. Research on treatment adherence is most relevant to medication-based biomedical prevention strategies, such as antiretroviral preexposure prophylaxis and acyclovir for herpes simplex virus-2. Three areas where HIV treatment adherence literature can inform research on such biomedical prevention strategies are 1) specialized methods for assessing medication adherence, 2) research findings emphasizing social context as an adherence determinant, and 3) promising behavioral interventions to improve adherence.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Center for Mental Health Research on AIDSNational Institute of Mental HealthBethesdaUSA